A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

NCT02937584 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD, Chronic Obstructive Pulmonary Disease

Interventions

DRUG: GP MDI (PT001) 14.4 μg
DRUG: FF MDI (PT005) 9.6 μg

Sponsor

Pearl Therapeutics, Inc.